SAN DIEGO, April 26, 2012 /PRNewswire/ -- Rempex Pharmaceuticals, Inc. today announced that Jennifer Cayer has joined the company as Chief Operating Officer. Ms. Cayer comes to Rempex from Conatus Pharmaceuticals, where she was co-founder and Senior Vice President of Corporate Development. At Rempex, she will be focusing on commercial planning and business development activities related to the company's antibacterial products.
Since the founding of Conatus in 2005, Ms. Cayer was responsible for all business development, marketing and intellectual property license agreement management. She identified and in-licensed two Phase 2-stage drug candidates and acquired a subsidiary of Pfizer, Inc. Previously, Ms. Cayer was Vice President of Corporate Development for Idun Pharmaceuticals, where she directed the out-licensing efforts that led to the company's acquisition by Pfizer in 2005. Prior to Idun, Ms. Cayer was Vice President, Business Development at Isis Pharmaceuticals where she executed multiple large pharmaceutical company strategic alliances including drug discovery and development collaborations, technology license agreements, and new company spinouts. Earlier in her career, she held various marketing, operational, and technical roles at Gensia Inc. and Puritan Bennett (Tyco). She received her B.S. in BioEngineering from the University of California, San Diego.
"Ms. Cayer has a clear track record of success in evaluating clinical stage assets and leading complicated licensing and acquisition transactions," stated Daniel Burgess, President and Chief Executive Officer of Rempex Pharmaceuticals. "Given that Rempex has multiple antibiotics in development, we believe she has an ideal background for helping us maximize the value of these assets and we very much look forward to having her as part of our team."
"I am excited to be joining Rempex at this critical time in the company's development," said Jennifer Cayer. "Rempex was founded by a world class team of experts in antibacterial drug discovery and development and they have already compiled a maturing pipeline in an area of great unmet medical need and of significant interest to the pharmaceutical industry. I look forward to working with the team to continue to add value to the company."
About Rempex Pharmaceuticals
Rempex Pharmaceuticals, Inc. is a biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. Rempex is focused on developing internally discovered new treatments for resistant gram-negative infections. The company has several product candidates in development and expects to file a New Drug Application (NDA) for its first product with the U.S. Food & Drug Administration (FDA) in 2013 and an Investigational New Drug Application (IND) for its second product in the next several months. Company website: www.rempexpharma.com
SOURCE Rempex Pharmaceuticals, Inc.